Dario Sterker

1.4k total citations
9 papers, 154 citations indexed

About

Dario Sterker is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Dario Sterker has authored 9 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Genetics. Recurrent topics in Dario Sterker's work include Pancreatic and Hepatic Oncology Research (3 papers), Kruppel-like factors research (3 papers) and Fibroblast Growth Factor Research (2 papers). Dario Sterker is often cited by papers focused on Pancreatic and Hepatic Oncology Research (3 papers), Kruppel-like factors research (3 papers) and Fibroblast Growth Factor Research (2 papers). Dario Sterker collaborates with scholars based in Switzerland and United States. Dario Sterker's co-authors include Francesco Hofmann, Vincent Romanet, Masato Murakami, Andreas Weiss, William R. Sellers, Nicolas Ebel, Mohamed Bentires‐Alj, Thomas Radimerski, Maria Schwaederlé and Sauveur-Michel Maira and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Dario Sterker

9 papers receiving 150 citations

Peers

Dario Sterker

MB

ONCOL

GENET

HEMAT

CR

King Pan Ng Singapore

Lorenz Bastian Germany

Monika Gothwal Germany

Yadira M. Soto-Feliciano United States

Takako Yokomizo‐Nakano Japan

Sergio Martínez-Høyer Spain

Hélène Lelièvre France

Emma Rousseau United States

Eva Grundschober Austria

Marco De Dominici United States

King Pan Ng Singapore

Dario Sterker

125 ×1.2

MB

35 ×0.5

ONCOL

29 ×0.6

GENET

52 ×1.5

HEMAT

27 ×1.2

CR

Citations per year, relative to Dario Sterker Dario Sterker (= 1×) peers King Pan Ng

Countries citing papers authored by Dario Sterker

Since Specialization

Citations

This map shows the geographic impact of Dario Sterker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dario Sterker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dario Sterker more than expected).

Fields of papers citing papers by Dario Sterker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dario Sterker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dario Sterker. The network helps show where Dario Sterker may publish in the future.

Co-authorship network of co-authors of Dario Sterker

This figure shows the co-authorship network connecting the top 25 collaborators of Dario Sterker. A scholar is included among the top collaborators of Dario Sterker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dario Sterker. Dario Sterker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Sterker, Dario, Kasper Renggli, Olivier Frey, et al.. (2021). A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues. Frontiers in Pharmacology. 12. 785851–785851. 8 indexed citations

2.

Laborde, Laurent, Dario Sterker, Hans-Peter Gschwind, et al.. (2018). Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models. Anti-Cancer Drugs. 29(7). 691–701. 1 indexed citations

3.

Laborde, Laurent, et al.. (2017). Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer. Cancer Chemotherapy and Pharmacology. 80(4). 869–878. 5 indexed citations

4.

Weiss, Andreas, Diana Graus Porta, Christelle Stamm, et al.. (2017). Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors. Cancer Research. 77(13_Supplement). 2103–2103. 5 indexed citations

5.

Porta, Diana Graus, Andreas Weiss, Robin A. Fairhurst, et al.. (2017). Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC. Cancer Research. 77(13_Supplement). 2098–2098. 8 indexed citations

6.

Ferretti, Stéphane, Dario Sterker, Markus Wartmann, et al.. (2016). Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials. Cancer Research. 76(14_Supplement). 1224–1224. 9 indexed citations

7.

Ferretti, Stéphane, et al.. (2014). Abstract 4638: NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer. Cancer Research. 74(19_Supplement). 4638–4638. 1 indexed citations

8.

Ebel, Nicolas, Vincent Romanet, Rita Andraos, et al.. (2013). JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease. Clinical Cancer Research. 19(22). 6230–6241. 59 indexed citations

9.

Hofmann, Irmgard, Andreas Weiss, Gaëlle Elain, et al.. (2012). K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo. PLoS ONE. 7(8). e44146–e44146. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact